
Drug prevents, delays Type 1 diabetes in 50% of those at risk, study finds
March 3 (UPI) -- Half of those at risk for Type 1 diabetes treated with a new drug remained disease-free five years later, a study published Wednesday by the journal Science Translational Medicine found. Conversely, 22% of people who did not receive the drug remained disease-free five years after the start of the study, the data showed. Advertisement The drug, teplizumab, is a monoclonal antibody -- a synthetic version of the cells produced by the human immune system -- developed by the biotechnology company Provention and is designed to prevent the onset of Type 1 diabetes. Those who developed Type 1 diabetes after receiving teplizumab did so about five years after receiving the new drug, compared with 27 months for study participants who received a placebo, the researchers said. "If ap...